AN2 Therapeutics Q3 loss narrows on lower expenses
ANTX•AN2 Therapeutics’ third-quarter net loss narrowed year over year to $7.96 million as research and development and general and administrative expenses fell. The company reported $80.2 million in cash and investments and expects its runway to fund operations into 2029.
1. Quarterly results
AN2 Therapeutics reported a third-quarter net loss of $7.96 million, a loss of $0.17 per share, and an operating loss of $8.67 million. Lower research and development spending, reflecting reduced preclinical, research and clinical trial costs, and lower general and administrative costs contributed to the narrower loss.
2. Pipeline and cash
The company advanced its clinical pipeline, including receiving regulatory clearance for a global Phase 2 PV study. It expects topline results from its M. abscessus Phase 2 trial in late 2027. Cash and investments totaled $80.2 million, which the company projects will fund operations into 2029.
